As per the research report, the size of the Middle East and Africa BCG Vaccine Market size is valued at USD XX million in 2020. It is expected to grow at a CAGR of X.XX% to reach USD XX million by 2025 during the forecast period 2020-2025. It captures 8% of the global market share.
BCG vaccine stands for Bacillus Calmette-Gurin (BCG) vaccine. It prevents TB and is the only vaccine in the market which could do that. A single dose is given to an infant soon after birth in countries with a high occurrence of TB. In countries in which TB is not a common occurrence, only high-risk infants are treated with it. Adults are only treated with this vaccine if their exposure to drug-resistant TB is a regular occurrence.
An increasing number of cases of TB all over the world particularly in the developing countries of APAC, rapid advancements in technology in the field of medical research on vaccines, and savory government policies and initiatives with improved funding are driving the growth of this market.
Adverse side-effects of this vaccine and supply bottlenecks all around the world are expected to hinder market growth in the forecast period.
This research report segmented and sub-segmented into the following categories:
Pediatrics is a clear market leader accounting for more than three-quarters of market share and is likely to gain even more in the forecast period. It is because BCG vaccination has become mandatory in most of the countries as part of the national immunization program. Moreover, the efficacy of the vaccine is reduced if it is not administered in infancy. The usage of this vaccine is highest in Kenya. Polio and hepatitis B vaccines are usually administered alongside it. It is the least unattractive market.
The leading companies leading in the MEA BCG Vaccine Market profiled in the report are Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory. Other players in the market include China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Demographics
5.1.1 Introduction
5.1.2 Pediatrics (0-18 years)
5.1.3 Adults (19-35 years)
5.1.4 Y-o-Y Growth Analysis, By Demographics
5.1.5 Market Attractiveness Analysis, By Demographics
5.1.6 Market Share Analysis, By Demographics
5.2 Product Type
5.2.1 BCG Vaccine Market
5.2.2 Immune BCG
5.2.3 Therapy BCG
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 End User
5.3.1 Pediatrics
5.3.2 Adults
5.3.4 Y-o-Y Growth Analysis, By End User
5.3.5 Market Attractiveness Analysis, By End User
5.3.6 Market Share Analysis, By End User
5.4 Applications
5.4.1 Home
5.4.2 Commercial
5.4.4 Y-o-Y Growth Analysis, By Applications
5.4.5 Market Attractiveness Analysis, By Applications
5.4.6 Market Share Analysis, By Applications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Demographics
6.1.3.3 By Product Type
6.1.3.4 By End User
6.1.3.5 By Applications
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Demographics
6.1.4.3 By Product Type
6.1.4.4 By End User
6.1.4.5 By Applications
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Demographics
6.1.5.3 By Product Type
6.1.5.4 By End User
6.1.5.5 By Applications
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi Pasteur
8.3 Japan BCG Laboratory
8.4 China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation)
8.5 Serum Institute of India Pvt. Ltd.
8.6 InterVax Ltd.
8.7 GreenSignal Bio Pharma Limited (GSBPL)
8.8 Statens Serum Institute
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
